Abbvie Biotherapeutics Inc.

Anesiva, Inc.

Rolf O Ehrhardt

Kenneth Hong

Christi L Parham

Leslie McEvoy

Jie Zhang

Methods and compositions are provided for the creation and screening of non-human animal models having many of the histologic characteristics of human psoriasis. Immunocompromised host animals are injected with a purified population of CD45Rb positive cells, which are tolerant of the host major histocompatibility antigens, but are mismatched at one or more minor antigens. The injected cells are stimulated with a pro-inflammatory cytokine, e.g. IL-12, and a polyclonal activating agent. The injected animals develop a chronic skin disorder that includes histological features observed in human psoriasis, e.g. rete pegs, severe acanthosis and infiltration of Th1 cells into the dermis.

Method for treating psoriasis

Methods of treating a patient suffering from psoriasis are disclosed, comprising administration of an antibody binding to interleukin-12 (IL-12).

The present invention concerns double-stranded NF-&#x3ba;B decoy oligodeoxynucleotide (NF-&#x3ba;B dsODN) molecules that contain a core sequence capable of specific binding to an NF-&#x3ba;B transcription factor. In a particular aspect, the invention concerns NF-&#x3ba;B decoy molecules that preferentially bind p50/p65 and/or cRel/p50 heterodimers over p50/p50 homodimers. In another aspect, the invention concerns NF-&#x3ba;B decoy molecules with improved binding affinity to p65.

Growing community of inventors

Mill Valley, CA, United States of America

Rolf O Ehrhardt